Clinigen Group plc Issue of Equity (3549Y)
December 04 2017 - 12:00PM
UK Regulatory
TIDMCLIN
RNS Number : 3549Y
Clinigen Group plc
04 December 2017
4 December 2017
Issue of Equity
Clinigen Group plc (AIM: CLIN, the "Group") announces that it
has made an application for the admission to trading on AIM of
17,925 ordinary shares of 0.1 pence each in the Group (the "New
Ordinary Shares"). These ordinary shares have been issued to
satisfy share options vesting under The Clinigen Group All Staff
Long Term Incentive Plan and The Clinigen Group All Staff JV Long
Term Incentive Plan and rank pari passu with the existing shares of
the Group. Admission to trading on AIM of the New Ordinary Shares
is anticipated to occur on 7 December 2017.
At admission the issued share capital of the Group will consist
of 122,286,083 ordinary shares, with no shares held in treasury.
The total number of voting rights in the Group will therefore be
122,286,083. This figure may be used by shareholders as the
denominator to determine if they are required to notify their
interests in, or a change to their interests in, the Group under
the Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283
495010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief
Financial Officer
Matt Parrish, Head of Investor
Relations
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20
Broker 7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners Tel: +44 (0) 20
7457 2020
Melanie Toyne-Sewell / Alex
Shaw / Deborah Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. Clinigen acquired Quantum Pharma in
November 2017.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEFSUFWLFWSEIE
(END) Dow Jones Newswires
December 04, 2017 13:00 ET (18:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Clinigen Group Plc (London Stock Exchange): 0 recent articles
More Clinigen Group News Articles